<code id='7F02D58C3A'></code><style id='7F02D58C3A'></style>
    • <acronym id='7F02D58C3A'></acronym>
      <center id='7F02D58C3A'><center id='7F02D58C3A'><tfoot id='7F02D58C3A'></tfoot></center><abbr id='7F02D58C3A'><dir id='7F02D58C3A'><tfoot id='7F02D58C3A'></tfoot><noframes id='7F02D58C3A'>

    • <optgroup id='7F02D58C3A'><strike id='7F02D58C3A'><sup id='7F02D58C3A'></sup></strike><code id='7F02D58C3A'></code></optgroup>
        1. <b id='7F02D58C3A'><label id='7F02D58C3A'><select id='7F02D58C3A'><dt id='7F02D58C3A'><span id='7F02D58C3A'></span></dt></select></label></b><u id='7F02D58C3A'></u>
          <i id='7F02D58C3A'><strike id='7F02D58C3A'><tt id='7F02D58C3A'><pre id='7F02D58C3A'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:9
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          AMAs digital advisors table RPM coding reform proposal, again
          AMAs digital advisors table RPM coding reform proposal, again

          You’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechnologyistransformingthelifes

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Readout Newsletter: Amylyx, Aurinia, and IQVIA

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo